Agile 3+ and Agile 4 well predict the occurrence of liverrelated events in patients with MASLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.